Brief: Genprex Receives Safety Review Committee Approval To Proceed To Final Cohort In Phase 1 Dose Escalation Trial In Advanced Non-Small Cell Lung Cancer

Genprex

14/12/2022 12:15

Dec 14 (Reuters) - Genprex Inc  GNPX.O :
    * GENPREX RECEIVES SAFETY REVIEW COMMITTEE APPROVAL TO
PROCEED TO
FINAL COHORT IN ACCLAIM-1 PHASE 1 DOSE ESCALATION TRIAL OF
REQORSA® IN COMBINATION WITH TAGRISSO® IN ADVANCED NON-SMALL
CELL LUNG CANCER
    * GENPREX INC - RECOMMENDATION TO ADVANCE TO INCREASED DOSE
IN
THIRD AND FINAL COHORT OF PHASE 1 PORTION OF TRIAL

Source text for Eikon:  ID:nPn8P3CK9a 
Further company coverage:  GNPX.O 
 ((Reuters.Briefs@thomsonreuters.com;))